Saturday , November 25 2017

Daily Archives: Sep 19, 2014

FDA Approves Once-Weekly Dulaglutide for Type 2 Diabetes

FDA Approves Once-Weekly Dulaglutide for Type 2 Diabetes Once-weekly dulaglutide was approved based on six clinical trials involving a total of 3,342 patients who received the drug. It was studied as a stand-alone therapy and in combination with metformin, sulfonylurea, thiazolidinedione, and prandial insulin. 

Read More »

Letter from the Editor, #747:

This was a busy week in the GLP-1 arena. An FDA advisory panel last week overwhelmingly recommended approval of Novo Nordisk’s latest weight-loss drug, Saxenda. This medication, which is liraglutide 3 mg, was recommended as an adjunct to diet and exercise in adults with a BMI of 30 or more, …

Read More »

MedPockets for Women with Diabetes

MedPockets for Women with Diabetes  For women patients who are looking for a convenient way to carry their diabetes meds and other necessities. Includes four built-in pockets perfect for insulin pumps, glucose meters, prosthesis, other essential health items, or personal items including cell phones, money, keys, credit cards, etc. Fashionable, …

Read More »

Saccharin May Impair Glucose Metabolism

Researchers from the Weizmann Institute of Science in Israel found that differences in gut microbes may explain why some people can handle artificial sweeteners just fine while in others the sweeteners lead to glucose intolerance. In studies in mice and people, researchers examined the interaction between gut microbes and consumption …

Read More »

The Staggering Cost of Diabetes

According to the ADA, total annual costs associated with diagnosed diabetes cases increased by 41% between 2007 and 2012, and the total estimated cost for care of those in the U.S. with diagnosed diabetes in 2012 was $245 billion. People diagnosed with diabetes spend about $13,700 per year on medical …

Read More »

Empagliflozin/linagliptin Combo Tablet Shows Sustained Reduction in BG

Boehringer Ingelheim, and Eli Lilly & Co. have presented results from a 52-week Phase III study demonstrating sustained efficacy of the investigational empagliflozin/linagliptin combination tablet in adults with T2DM already taking metformin and in those who were previously untreated. The results, presented during the 50th Annual Meeting of the European …

Read More »